JLJacopo Lin

Jacopo Lin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jacopo Lin has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of Prophylactic Incisional Negative Pressure Wound Therapy on Surgical Site Infection After Emergency Laparotomy: An Updated Meta‐Analysis With Trial Sequential Analysis

    by Ana Luíza Rocha Soares Menegat, Brenda Luana Rocha Soares Menegat, Sara Bravin, Jacopo Lin, Henrique Wiederkehr

    Introduction: Patients undergoing emergency laparotomy are at high risk of surgical site infections (SSI), which contribute substantially to postoperative morbidity. Incisional negative pressure wound therapy (iNPWT) has been shown to reduce the incidence of SSI following elective surgery, however, its effectiveness in the emergency setting remains uncertain. Therefore, we conducted a systematic review and meta‐analysis to evaluate the effectiveness of iNPWT in reducing SSI after emergency laparotomy. Methods: We searched PubMed, Embase, and Cochrane through November 2025 for randomized controlled trials (RCTs) and observational studies comparing iNPWT to standard dressings after emergency laparotomy. Odds ratios (OR) and mean differences (MD) were pooled for relevant outcomes with 95% confidence intervals using random‐effects and inverse variance weighting. A two‐tailed p ‐value < 0.05 was considered significant. Prespecified subgroup analyses restricted to RCTs were performed. Statistical heterogeneity was assessed using the I 2 statistic. Results: Fifteen studies (6 RCTs and 9 observational) including 3369 patients were analyzed. It was found that iNPWT was associated with significantly lower odds of overall (OR 0.36; p = 0.0003), superficial, and deep SSI, with consistent findings in RCT‐only analysis (OR 0.41; p = 0.0221). iNPWT was also associated with lower odds of seroma (OR 0.57; p = 0.0325), with consistent results observed in RCT‐only analyses (OR 0.54; p = 0.025). Hospital length of stay was shorter in the iNPWT group (MD −1.49 days; p = 0.04), and iNPWT was associated with lower odds of wound dehiscence (OR 0.47; p = 0.0062), however, these findings were not confirmed in RCT‐only analyses. Postoperative complications, classified according to the Clavien–Dindo system, did not differ between groups (OR 0.93; p = 0.4973). Overall mortality was comparable between groups, although iNPWT was associated with higher follow‐up mortality. This finding was not confirmed in RCTs. Conclusion: In patients undergoing emergency laparotomy, iNPWT was associated with reduced odds of SSI and wound‐related complications compared with standard dressings. Although iNPWT was associated with higher follow‐up mortality, this finding was not confirmed in RCT‐only analyses.

  • Efficacy of Fibroblast Growth Factor Receptor Inhibitors (FGFRi) in Locally Advanced or Metastatic Cholangiocarcinoma With FGFR Fusions or Rearrangements

    by Abdul Rehman, Jacopo Lin, Sakshi Arora, Jonathan D. Mohnkern, Dhvanit Rajdeep, Rubia A.S. Lopes Seixas

    Objectives: The efficacy of various FGFR inhibitors (FGFRi) has been reported for advanced cholangiocarcinoma patients harboring FGFR fusion genes or rearrangements. However, the pooled efficacy of FGFRi is still lacking. Methods: PubMed, Cochrane, and Embase databases were systematically searched from inception to Jan 2026 for studies evaluating the efficacy of FGFRi in advanced cholangiocarcinoma patients previously treated with chemotherapy. The primary outcomes were the objective response rate, disease control rate, progression-free survival, and overall survival. Secondary outcomes included safety parameters. A proportional meta-analysis was performed using a random-effects model.Heterogeniety was assessed using I 2 statistics. Results: Eight studies with 463 patients were included. In the pooled analysis, the objective response rate was 40.4% (n=171/463; 95% CI: 31.64%-49.81%), and the disease control rate was 92.48% (n=368/435; 95% CI: 81.68%-98.72%). Progression-free survival was 64.3% (n=164/255; 95% CI: 58.24%-69.96%) and 37.33% (n=84/255; 95% CI: 31.26%-43.84%) at 6 and 12 months, respectively. Overall survival rates were 91.45% (n=139/152; 95% CI: 85.83%-94.97%) and 70.67% (n=159/225; 95% CI: 64.39%-76.25%) at 6 and 12 months, respectively. The common adverse events were hyperphosphatemia (75.4%), alopecia (44.53%), stomatitis (33.20%), diarrhea (32.15%), fatigue (33.64%), dry eyes (25.20%), nail discolouration (17.38%), ALT elevation (14.53%), and AST elevation (16.93%). Conclusions: Our analysis suggests that FGFR alteration testing and the use of FGFRi as an effective alternative option in advanced cholangiocarcinoma patients previously treated with chemotherapy.

  • Open Access

    Long-term outcomes of bioprosthetic tricuspid valves: a systematic review of studies published over the last 20 years

    by Edoardo Zancanaro, Michele Di Mauro, Giovanni Alfonso Chiariello, Daniel Sebastian Dohle, Karl-Patrik Kresoja, Jacopo Lin, Gaia De Angelis, Sebastian Rosch, Karl-Philipp Rommel, Michele De Bonis, et al.

    Although the use of bioprostheses for tricuspid valve replacement (bTVR) has always been controversial in terms of results, their long-term durability is not well described. This systematic review aimed to identify, assess the quality, and review the outcomes in studies reporting on long-term outcomes after bTVR published over the last 20 years. Medline, Embase, and Cochrane CENTRAL were searched for studies reporting on at least five years of follow-up after bTVR. Cohort characteristics, definitions of structural valve deterioration (SVD), whose definition followed the criteria, and outcomes were summarized. The risk of bias in included studies was assessed using the Cochrane QUIPS tool. Ninteen studies, including 2541 patients were identified. The commonest implanted bioprosthesis was porcine-type with 1950 patients receiving this valve, followed by bovine pericardial (BP) type with 591 cases. Freedom from SVD in studies reporting outcomes up to 5–10 years ranged from 80% to 100% and in studies reporting to 15–20 years from 47% to 90%. Freedom from re-operation in studies reporting up to 5–10 years ranged from 94.7% to 100% and in studies reporting up to 15–20 years ranged from 49% to 95%. Reports of post-operative echocardiography were lacking, despite the heavy reliance on echocardiography for SVD diagnosis. There is considerable variability in reporting bTVR-related long-term outcomes. As such, it is difficult to generate an unbiased, generalizable understanding of long-term outcomes after bTVR across the spectrum of tricuspid disease phenotypes. Future clinical research will require more attention and detailed data report to fil such a gap.